The University of Alabama at Birmingham recently announced a collaboration with pharmaceutical behemoth vaccine producer Merck, to perform Gardasil 9 HPV vaccine trials on postpartum mothers between the ages of 16 and 26, immediately after having their children at the UAB hospital.
The researchers somehow believe not enough people are being vaccinated for HPV, and the desired outcome of the study is officially to get more young women vaccinated.
According to Vaccine Impact:
Merck and UAB want to test the vaccine on 16 to 26 year old postpartum mothers because “the immune response in young women is less robust than in adolescents,” and because “no studies have examined immunogenicity in postpartum women specifically.”
Therefore, 16 to 26 year old young mothers who have just given birth at the UAB hospital will become test subjects of the Gardasil 9 vaccine.
The study is scheduled to start on June 1, 2018.
The “Responsible Party”This post was originally published on this site